Close Menu

stock price

Sequenom paced the gainers, while PacBio saw the biggest decline in what turned out to be a choppy month for the GenomeWeb Index.

Fluidigm and Meridian Bioscience led the gainers in the GenomeWeb Index for the month, while T2 Bio and PacBio's shares saw the biggest drops. 

Roche's investment in Foundation of up to $1.2B sent Foundation's stock soaring. Otherwise, firms in the GenomeWeb Index saw a mixed month. 

Along with Exact Sciences, the other big gainers in the GWDN Index were Illumina, Myriad Genetics, and Sequenom. 

The company said that CMS will correct a clinical lab fee schedule that set reimbursement for the Cologuard test well below the amount set in November.


NanoString topped the 15 firms in the GWDN Index that saw a gain in their stock price in November, while Agilent led the decliners for the month.

Officials said the firm remains confident in its HBV drug despite investors' negative reaction to Phase IIa data.


CMS has issued its final payment decision for Exact Sciences' Cologuard test and will reimburse providers $502 per test.

NEW YORK (GenomeWeb) – Stocks in the omics research tools and molecular diagnostics space were mixed in August as the GenomeWeb Daily News Index moved up almost 3 percent from July, but nearly half of the firms in the index suffered a loss in share price month over month.

NEW YORK (GenomeWeb) – Investment banks Goldman Sachs and Leerink Partners initiated coverage of T2 Biosystems today with a Neutral and Market Perform rating, respectively, on the firm's stock.


The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.